Can Fite Biopharma

Can Fite Biopharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Can Fite Biopharma (CANF.TA) as of Oct 17, 2026 is 0.29. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 0.28 — a change of 4.42% (higher).

EV/FCF

0.29

YoY

4.42%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Can Fite Biopharma is 2025 0.29 . EV/FCF (Enterprise Value to Free Cash Flow) of Can Fite Biopharma was 2024 0.28 . It decreases by 4.42% higher compared to the previous year.

The Can Fite Biopharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-0.42 USD
Jan 1, 2019
-0.27 USD
Jan 1, 2020
0.22 USD
Jan 1, 2021
1.35 USD
Jan 1, 2022
0.21 USD
Jan 1, 2023
0.38 USD
Jan 1, 2024
0.28 USD
Jan 1, 2025
0.29 USD
The Can Fite Biopharma EV/FCF history
YEAREV/FCFYoY
0.29+4.42%
0.28-27.21%
0.38+82.80%
0.21-84.57%
1.35+525.35%
0.22-178.85%
-0.27-35.14%
-0.42+86.42%
-0.23-207.50%
0.21-91.19%
2.40-319.60%
-1.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Can Fite Biopharma Stock analysis

What does Can Fite Biopharma do? Can-Fite Biopharma Ltd. is an Israeli company specializing in the development of drugs for inflammatory diseases and cancer. It was founded in 1994 by Prof. Pnina Fishman and is headquartered in Petach Tikva, Israel. The company initially focused on studying the function of adenosine receptors in central nervous system diseases, but later expanded to develop drugs for inflammatory diseases and cancer. Can-Fite went public in 2007 and has been able to finance its research projects through investors and partnerships. The company's business model revolves around developing an innovative portfolio of drugs for immune system disorders and cancer by targeting adenosine receptors. It aims to expand its drug pipeline to successfully treat a wide range of diseases. Can-Fite's drug pipeline is divided into different areas, including inflammatory diseases, cancer, and ophthalmology. The company has already brought several drugs to market or is in the clinical testing phase, including CF101 for rheumatoid arthritis and psoriasis, Namodenoson for liver cancer, and Piclidenoson for autoimmune diseases. Overall, Can-Fite Biopharma Ltd. is a promising company focused on developing innovative drugs for inflammatory diseases and cancer. Can Fite Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Can Fite Biopharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Can Fite Biopharma is 0.29 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Can Fite Biopharma changed from 0.28 to 0.29, representing a 4.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Can Fite Biopharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Can Fite Biopharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Can Fite Biopharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Can Fite Biopharma